ClavystBio
About
ClavystBio ClavystBio was established in 2021 by CLA Real Estate Holdings, a wholly-owned subsidiary of Temasek. Singapore's sovereign wealth fund. Since 2022, the firm has committed over $220M to biotech, diagnostics, and digital health companies, with 23 total investments including 11 direct companies and 3 early-stage VC fund positions. Focus areas include cell and gene therapy, biomarkers, digital health, and life sciences commercialization. The firm operates Node 1, a physical space in Sin
Industries
Stage focus
SeedSeries A
Geography
Southeast Asia
Notable investments
- NSG BioLabs
Raising from ClavystBio?
I've worked with founders across the industrial stack. If ClavystBio is on your list, I can help you map the introduction path, sharpen the narrative, and run a tight process.
Talk to Dan